Clinical evidence remains mixed
10.1248/bpb.b13-00469 315 Yoon HeeraY
It optimizes body composition by promoting protein synthesis and fat breakdown
Some people in specific contextsmetabolic syndrome, prediabetes, comprehensive health optimizationmay benefit from evidence-based metabolic support supplements
GHK-Cus gene modulation capacity was documented in a landmark microarray analysis by Pickart et al., identifying 4,000+ gene targets including VEGF upregulation (angiogenesis), SOD2 upregulation (oxidative defense), and downregulation of pro-inflammatory cytokine genes including TNF- and IL-6
"We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology." Two additional clinical trials funded by pharmaceutical companies showed no difference between carriers and non-carriers, although these studies used longer-acting GLP-1 drugs